Predictive role of repair enzymes in the efficacy of cisplatin combinations in pancreatic and lung cancer

Anticancer Research

Volumn 34, Issue 1, 2014, Pages 435-442

  Peters, Godefridus J ^a   Avan, Abolfazl ^a   Ruiz, Marielle Gallegos ^a   Orsini, Vanessa ^a   Avan, Amir ^a   Giovannetti, Elisa ^a   Smit, Egbert F ^b  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Cisplatin; DNA repair; ERCC1; Gemcitabine; Non small cell lung cancer; Pancreatic cancer; Review.; Ribonucleotide reductase; XPD

Indexed keywords

CISPLATIN; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; GEMCITABINE; POLYDEOXYRIBONUCLEOTIDE SYNTHASE; ANTINEOPLASTIC AGENT; CARBOPLATIN; DEOXYCYTIDINE; DRUG DERIVATIVE; RIBONUCLEOTIDE REDUCTASE; TUMOR MARKER;

CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CONFERENCE PAPER; DNA ADDUCT; DNA DAMAGE; DNA REPAIR; DRUG EFFICACY; ENZYME ACTIVITY; EXCISION REPAIR; GENE EXPRESSION; HUMAN; MUTATIONAL ANALYSIS; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PHARMACOGENETICS; PREDICTION; PROTEIN EXPRESSION; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT OUTCOME; TREATMENT RESPONSE; ERCC1; LUNG TUMOR; METABOLISM; NON-SMALL CELL LUNG CANCER; PANCREAS CANCER; PANCREAS TUMOR; PROGNOSIS; REVIEW; XPD;

CISPLATIN; DNA REPAIR; ERCC1; GEMCITABINE; NON-SMALL CELL LUNG CANCER; PANCREATIC CANCER; REVIEW; RIBONUCLEOTIDE REDUCTASE; XPD;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CISPLATIN; DEOXYCYTIDINE; DNA REPAIR ENZYMES; HUMANS; LUNG NEOPLASMS; PANCREATIC NEOPLASMS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84897022059     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (46)

1. Siegel R, Naishadham D and Jemal A:Cancer statistics, 2012. CA Cancer J Clin 62: 10-29, 2012.
2. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, Zhu J, Johnson DH and Eastern Cooperative Oncology Group: Comparison of four chemotherapy regimens for advanced non-small cell lung cancer. N Engl J Med 346: 92-98, 2002.
3. Scagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C, Serwatowski P, Gatzemeier U, Digumarti R, Zukin M, Lee JS, Mellemgaard A, Park K, Patil S, Rolski J, Goksel T, de Marinis F, Simms L, Sugarman KP and Gandara D: Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 26: 3543-3551, 2008.
4. van Meerbeeck JP, Gaafar R, Manegold C, Van Klaveren RJ, Van Marck EA, Vincent M, Legrand C, Bottomley A, Debruyne C, Giaccone G; European Organisation for Research and Treatment of Cancer Lung Cancer Group and National Cancer Institute of Canada: Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. J Clin Oncol 23: 6881-6889, 2005.
5. Sancar A: DNA repair in humans. Annu Rev Genet 29: 69-105, 1995.
6. Postel-Vinay S, Vanhecke E, Olaussen KA, Lord CJ, Ashworth A and Soria JC: The potential of exploiting DNA-repair defects for optimizing lung cancer treatment. Nat Rev Clin Oncol 9: 144-155, 2012.
7. Siddik ZH: Mechanisms of action of cancer chemotherapeutic agents: DNA-interactive alkylating agents and antitumour platinum-based drugs. In: The Cancer Handbook. Alison MR (ed.). Nature Publishing Group, London, UK, pp. 1295-1313, 2002.
8. Giovannetti E, Toffalorio F, De Pas T and Peters GJ: Pharmacogenetics of conventional chemotherapy in non-small-cell lung cancer: A changing landscape? Pharmacogenomics 13: 1073-1086, 2012.
9. Mathiaux J, Le Morvan V, Pulido M, Jougon J, Bégueret H and Robert J: Role of DNA repair gene polymorphisms in the efficiency of platinum-based adjuvant chemotherapy for non-small cell lung cancer. Mol Diagn Ther 15(3): 159-166, 2011.
10. Goldstein DB, Tate SK and Sisodiya SM: Pharmacogenetics goes genomic. Nat Rev Genet 4: 937-947, 2003.
11. Bergman AM, Ruiz van Haperen VWT, Veerman G, Kuiper CM and Peters GJ: Synergistic interaction between gemcitabine and cisplatin in vitro. Clin Cancer Res 2: 521-530, 1996.
12. Braakhuis BJM, Ruiz van Haperen VWT, Welters MJP, Peters GJ. Schedule-dependent therapeutic efficacy of the combination of gemcitabine and cisplatin in head and neck cancer xenografts. Eur J Cancer 31A: 2335-2340, 1995
13. Van Moorsel CJA, Pinedo HM, Veerman G, Bergman AM, Kuiper CM, Vermorken JB, Van der Vijgh WJF and Peters GJ: Mechanisms of synergism between cisplatin and gemcitabine in ovarian and non-small cell lung cancer cell lines. Br J Cancer 35: 808-814, 1999.
14. Van Moorsel CJA, Pinedo HM, Veerman G, Vermorken JB, Postmus PE and Peters GJ: Scheduling of gemcitabine and cisplatin in Lewis lung tumour bearing mice. Eur J Cancer 35:808-814, 1999.
15. Van Moorsel CJA, Pinedo HM, Smid K, Comijn EM, Voorn DA, Veerman G, Lakerveld B, Van der Vijgh WJF, Giaccone G, Postmus PE, Peters GJ. Schedule dependent pharmacodynamic effects of gemcitabine and cisplatin in mice bearing Lewis Lung murine non-small cell lung tumors. Eur J Cancer 36: 2420-2429, 2000.
16. Peters GJ, Van Moorsel CJ, Lakerveld B, Smid K, Noordhuis P, Comijn EC, Weaver D, Willey JC, Voorn D, Van der Vijgh WJ and Pinedo HM: Effects of gemcitabine on cis-platinum-DNA adduct formation and repair in a panel of gemcitabine and cisplatin-sensitive or -resistant human ovarian cancer cell lines. Int J Oncol 28(1): 237-244, 2006.
17. Yang LY, Li L, Jiang H, Shen Y and Plunkett W: Expression of ERCC1 antisense RNA abrogates gemcitabine-mediated cytotoxic synergism with cisplatin in human colon tumor cells defective in mismatch repair but proficient in nucleotide excision repair. Clin Cancer Res 6: 773-781, 2000.
18. Selvakumaran M, Pisarcik DA, Bao R, Yeung AT and Hamilton TC. Enhanced cisplatin cytotoxicity by disturbing the nucleotide excision repair pathway in ovarian cancer cell lines. Cancer Res 63: 1311-1316, 2003.
19. Van Moorsel CJA, Smid K, Voorn DA, Bergman AM, Pinedo HM and Peters GJ: Effects of gemcitabine and cis-platinum combinations on ribonucleotide and deoxyribonucleotide pools in ovarian cancer cell lines. Int J Oncol 22: 201-207, 2003.
20. Elnaggar M, Giovannetti E and Peters GJ: Molecular targets of gemcitabine action: Rationale for development of novel drugs and drug combinations. Curr Pharm. Design 18: 2811-2829, 2012.
21. Danesi R, Pasqualetti G, Giovannetti E, Crea F, Altavilla G, Del Tacca M and Rosell R: Pharmacogenomics in non-small cell lung cancer chemotherapy. Adv Drug Deliv Rev 61: 408-417, 2009.
22. Pfister DG, Johnson DH, Azzoli CG, Sause W, Smith TJ, Baker S, Jr., Olak J, Stover D, Strawn JR, Turrisi AT, Somerfield MR and American Society of Clinical Oncology: American society of clinical oncology treatment of unresectable non-small-cell lung cancer guideline: Update 2003. J Clin Oncol 22: 330-353, 2004.
23. Smit EF, van Meerbeeck JP, Lianes P, Debruyne C, Legrand C, Schramel F, Smit H, Gaafar R, Biesma B, Manegold C, Neymark N, Giaccone G; Europea Organization for Research and Treatment of Cancer Lung Cancer Group. Three-arm randomized study of two cisplatin-based regimens and paclitaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group-EORTC 08975. J Clin Oncol 21: 3909-3917, 2003.
24. Lord RV, Brabender J, Gandara D, Alberola V, Camps C, Domine M, Cardenal F, Sánchez JM, Gumerlock PH, Tarón M, Sánchez JJ, Danenberg KD, Danenberg PV and Rosell R: Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin Cancer Res 8: 2286-2291, 2002.
25. Olaussen KA, Dunant A, Fouret P, Brambilla E, André F, Haddad V, Taranchon E, Filipits M, Pirker R, Popper HH, Stahel R, Sabatier L, Pignon JP, Tursz T, Le Chevalier T, Soria JC and IALT Bio Investigators: DNA repair by ERCC1 in non-small cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 355: 983-991, 2006.
26. Bhagwat NR, Roginskaya VY, Acquafondata MB, Dhir R, Wood RD and Niedernhofer LJ: Immunodetection of DNA repair endonuclease ERCC1-XPF in human tissue. Cancer Res 69: 6831-6838, 2009.
27. Friboulet L, Olaussen KA, Pignon JP, Shepherd FA, Tsao MS, Graziano S, Kratzke R, Douillard JY, Seymour L, Pirker R, Filipits M, André F, Solary E, Ponsonnailles F, Robin A, Stoclin A, Dorvault N, Commo F, Adam J, Vanhecke E, Saulnier P, Thomale J, Le Chevalier T, Dunant A, Rousseau V, Le Teuff G, Brambilla E and Soria JC: ERCC1 isoform expression and DNA repair in non-small cell lung cancer. N Engl J Med 368: 1101-1110, 2013.
28. Chen S, Zhang J, Wang R, Luo X and Chen H: The platinum-based treatments for advanced non-small cell lung cancer, is low/negative ERCC1 expression better than high/positive ERCC1 expression? A meta-analysis. Lung Cancer 70: 63-70, 2010.
29. Ceppi P, Volante M, Novello S, Rapa I, Danenberg KD, Danenberg PV, Cambieri A, Selvaggi G, Saviozzi S, Calogero R, Papotti M and Scagliotti GV: RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine Ann. Oncol 17: 1818-1825, 2006.
30. Bepler G, Kusmartseva I, Sharma S, Gautam A, Cantor A, Sharma A and Simon G: RRM1 modulated in vitro and in vivo efficacy of gemcitabine and platinum in non-small cell lung cancer. J Clin Oncol 24: 4731-4737, 2006.
31. Bepler G, Williams C, Schell MJ, Chen W, Zheng Z, Simon G, Gadgeel S, Zhao X, Schreiber F, Brahmer J, Chiappori A, Tanvetyanon T, Pinder-Schenck M, Gray J, Haura E, Antonia S and Fischer JR: Randomized international phase III trial of ERCC1 and RRM1 expression-based chemotherapy versus gemcitabine/carboplatin in advanced non-small cell lung cancer. J Clin Oncol 31(19): 2404-2412, 2013.
32. Zucali PA, Giovannetti E, Destro A, Mencoboni M, Ceresoli GL, Gianoncelli L, Lorenzi E, De Vincenzo F, Simonelli M, Perrino M, Bruzzone A, Thunnissen E, Tunesi G, Giordano L, Roncalli M, Peters GJ and Santoro A: Thymidylate synthase and excision repair-cross-complementing group-1 as predictors of responsiveness in mesothelioma patients treated with pemetrexed-carboplatin. Clin. Cancer Res 17: 2581-2590, 2011.
33. Yu JJ, Lee KB, Mu C, Li Q, Abernathy TV, Bostick-Bruton F and Reed E. Comparison of two human ovarian carcinoma cell lines (a2780/cp70 and mcas) that are equally resistant to platinum, but differ at codon 118 of the ercc1 gene. Int J Oncol 16: 555-560, 2000.
34. Isla D, Sarries C, Rosell R, Alonso G, Domine M, Taron M, Lopez-Vivanco G, Camps C, Botia M, Nunez L, Sanchez-Ronco M, Sanchez JJ, Lopez-Brea M, Barneto I, Paredes A, Medina B, Artal A and Lianes P: Single nucleotide polymorphisms and outcome in docetaxel-cisplatin-treated advanced non-small cell lung cancer. Ann Oncol 15: 1194-1203, 2004.
35. Ryu JS, Hong YC, Han HS, Lee JE, Kim S, Park YM, Kim YC and Hwang TS: Association between polymorphisms of ercc1 and xpd and survival in non-small cell lung cancer patients treated with cisplatin combination chemotherapy. Lung Cancer 44: 311-316, 2004.
36. Tiseo M, Giovannetti E, Tibaldi C, Camerini A, Di Costanzo F, Barbieri F, Burgers JA, Vincent A, Peters GJ, Smit EF and Ardizzoni A: Pharmacogenetic study of patients with advanced non-small cell lung cancer treated with second-line pemetrexed or pemetrexed-carboplatin. Lung Cancer 78: 92-99, 2012.
37. Gurubhagavatula S, Liu G, Park S, Zhou W, Su L, Wain JC, Lynch TJ, Neuberg DS and Christiani DC: XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small cell lung cancer patients treated with platinum chemotherapy. J Clin Oncol 22(13): 2594-2601, 2004.
38. Tibaldi C, Giovannetti E, Vasile E, Mey V, Laan AC, Nannizzi S, Di Marsico R, Antonuzzo A, Orlandini C, Ricciardi S, Del Tacca M, Peters GJ, Falcone A and Danesi R: Correlation of CDA, ERCC1, and XPD polymorphisms with response and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients. Clin Cancer Res 14: 1797-1803, 2008.
39. Wei SZ, Zhan P, Shi MQ, Shi Y, Qian Q, Yu LK and Song Y: Predictive value of ercc1 and xpd polymorphism in patients with advanced non-small cell lung cancer receiving platinum-based chemotherapy: A systematic review and meta-analysis. Med Oncol 28: 315-321, 2011.
40. Conroy T, Desseigne F, Ychou M, Bouché O, Guimbaud R, Bécouarn Y, Adenis A, Raoul JL, Gourgou-Bourgade S, de la Fouchardière C, Bennouna J, Bachet JB, Khemissa-Akouz F, Péré-Vergé D, Delbaldo C, Assenat E, Chauffert B, Michel P, Montoto-Grillot C, Ducreux M; Groupe Tumeurs Digestives of Unicancer and PRODIGE Intergroup: FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 364: 1817-1825, 2011.
41. Reni M, Cordio S, Milandri C, Passoni P, Bonetto E, Oliani C, Luppi G, Nicoletti R, Galli L, Bordonaro R, Passardi A, Zerbi A, Balzano G, Aldrighetti L, Staudacher C and Villa E, Di Carlo V: Gemcitabine versus cisplatin, epirubicin, fluorouracil, and gemcitabine in advanced pancreatic cancer: A randomised controlled multicentre phase III trial. Lancet Oncol 6: 369-376, 2005.
42. Kamikozuru H, Kuramochi H, Hayashi K, Nakajima G and Yamamoto M: ERCC1 codon 118 polymorphism is a useful prognostic marker in patients with pancreatic cancer treated with platinum-based chemotherapy. Int J Oncol 32: 1091-1096, 2008.
43. Giovannetti E, Pacetti P, Reni M, Leon LG, Mambrini A, Vasile E, Ghidini M, Funel N, Lucchesi M, Cereda S, Peters GJ and Cantore M: Association between DNA repair polymorphisms and survival in pancreatic cancer patients treated with combination chemotherapy. Pharmacogenomics 12: 1641-1652, 2011.
44. Avan A, Pacetti P, Reni M, Mambrini A, Cereda S, Peters GJ, Cantore M and Giovannetti: Prognostic factors in gemcitabine/cisplatin polychemotherapy regimens in pancreatic cancer: XPD-Lys751Gln polymorphism strikes back. Int. J Cancer 133: 1016-1022, 2013.
45. Martens-de Kemp SR, Dalm SU, Wijnolts FMJ, Brink A, Honeywell RJ, Peters GJ, Braakhuis BJM and Brakenhoff RH: DNA-bound platinum is the major determinant of cisplatin sensitivity in head and neck squamous carcinoma cells. PLoS One 8(4): e61555, 2013.
46. Galvani E, Peters GJ and Giovannetti E: EGF receptor-targeted therapy in non-small cell lung cancer: Role of germline polymorphisms in outcome and toxicity. Future Oncol 8: 1015-1029, 2012.